Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular &amp; Electrodiagnostic Medicine Annual Meeting.

Medicine

Health & Fitness

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Share Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Sign up to save your podcasts

Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT